– USA, CA – TRIO Pharmaceuticals, a biotechnology company advancing novel multi-functional antibody treatments for cancers with high unmet medical need, announced the appointment of Dr. Mikael Dolsten (M.D., Ph.D.) to its Board as independent director and Chairman.
About Dr. Mikael Dolsten
Dr. Mikael Dolsten served for more than 15 years as CSO of Pfizer Inc. and President of Pfizer Research and Development, and as a member of Pfizer’s Executive Leadership Team. During his tenure at Pfizer, the company achieved more than 36 drug approvals, including antibodies, small molecules, vaccines, and generic medicines.
In his long career in biopharma, Dr. Mikael Dolsten has held leadership roles at some of the largest biopharma companies in the world, including Wyeth Research, Boehringer Ingelheim, AstraZeneca, and Pharmacia. During this time, he has contributed to approximately 50 drug and vaccine approvals. In his various roles, he has participated in transactions exceeding $100 billion in combined value.
Beyond his executive leadership positions, Dr. Mikael Dolsten has sat on numerous public and private boards, including Agilent Technologies, Novo Nordisk, Rocket Pharmaceuticals, Orbis Medicine, ChAi Discovery, Fair Journey Biologics, and Arbor Biotechnologies. Additionally, he serves as an investment advisor to Blackstone Life Sciences, Google’s GV, Canaan Partners, and Bain & Co.
His advisory roles include public health initiatives, where he has collaborated with the U.S. and U.K. governments and served organizations including the Scripps Research Institute and the Foundation for the National Institutes of Health. He has served on the board of directors and the Research and Development Leadership Forum of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Dr. Mikael Dolsten has published more than 150 scientific articles in peer-reviewed journals in the fields of oncology, inflammation, and molecular cell biology. He regularly lectures at scientific and pharmaceutical conferences across the globe. During the COVID-19 pandemic, he served as scientific leader for the development of Pfizer’s mRNA-based vaccine and the key oral antiviral Paxlovid.
About Trio Pharmaceuticals
Trio Pharmaceutics is a preclinical biopharma focused on developing a new antibody modality, the TRAILBody, to fight solid and liquid tumors with high unmet medical needs. TRAILBodies kill tumor cells without the need for conjugated toxic drugs. This leaves healthy cells untouched with the potential to overcome the relapses and resistance that often diminish the response rate and durability of current therapies. Trio recently closed a $3.1 million financing round led by Friedman Bioventure Fund, with additional support from the Myeloma Investment Fund, the venture philanthropy arm of the Multiple Myeloma Research Foundation, NuFund Venture Group, and other investors.
For more information: https://www.triopharmaceuticals.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.